JP4368421B2 - Ｓ―（―）―ｎ―プロパルギル―１―アミノインダンを含む医薬組成物 - Google Patents

Ｓ―（―）―ｎ―プロパルギル―１―アミノインダンを含む医薬組成物 Download PDF

Info

Publication number
JP4368421B2
JP4368421B2 JP50580698A JP50580698A JP4368421B2 JP 4368421 B2 JP4368421 B2 JP 4368421B2 JP 50580698 A JP50580698 A JP 50580698A JP 50580698 A JP50580698 A JP 50580698A JP 4368421 B2 JP4368421 B2 JP 4368421B2
Authority
JP
Japan
Prior art keywords
propargyl
pharmaceutical composition
aminoindan
pharmaceutically acceptable
injury
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
JP50580698A
Other languages
English (en)
Japanese (ja)
Other versions
JP2000514453A (ja
JP2000514453A5 (cg-RX-API-DMAC10.html
Inventor
レビー，ルース
ユーディン，モーサ・ビー・エイチ
フィンバーグ，ジョン・ピー・エム
コーエン，サッソン
スターリング，ジェフ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Technion Research and Development Foundation Ltd
Original Assignee
Technion Research and Development Foundation Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Technion Research and Development Foundation Ltd filed Critical Technion Research and Development Foundation Ltd
Publication of JP2000514453A publication Critical patent/JP2000514453A/ja
Publication of JP2000514453A5 publication Critical patent/JP2000514453A5/ja
Application granted granted Critical
Publication of JP4368421B2 publication Critical patent/JP4368421B2/ja
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C211/00—Compounds containing amino groups bound to a carbon skeleton
    • C07C211/33—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to carbon atoms of rings other than six-membered aromatic rings
    • C07C211/39—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to carbon atoms of rings other than six-membered aromatic rings of an unsaturated carbon skeleton
    • C07C211/41—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to carbon atoms of rings other than six-membered aromatic rings of an unsaturated carbon skeleton containing condensed ring systems
    • C07C211/42—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to carbon atoms of rings other than six-membered aromatic rings of an unsaturated carbon skeleton containing condensed ring systems with six-membered aromatic rings being part of the condensed ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2602/00—Systems containing two condensed rings
    • C07C2602/02—Systems containing two condensed rings the rings having only two atoms in common
    • C07C2602/04—One of the condensed rings being a six-membered aromatic ring
    • C07C2602/08—One of the condensed rings being a six-membered aromatic ring the other ring being five-membered, e.g. indane

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
JP50580698A 1996-07-11 1997-06-20 Ｓ―（―）―ｎ―プロパルギル―１―アミノインダンを含む医薬組成物 Expired - Lifetime JP4368421B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
IL11883696A IL118836A (en) 1996-07-11 1996-07-11 Pharmaceutical compositions comprising s-(-)-n-propargyl-1-aminoindan
IL118836 1996-07-11
PCT/IL1997/000205 WO1998002152A1 (en) 1996-07-11 1997-06-20 Pharmaceutical compositions comprising s-(-)-n-propargyl-1-amino indan

Publications (3)

Publication Number Publication Date
JP2000514453A JP2000514453A (ja) 2000-10-31
JP2000514453A5 JP2000514453A5 (cg-RX-API-DMAC10.html) 2005-03-10
JP4368421B2 true JP4368421B2 (ja) 2009-11-18

Family

ID=11069065

Family Applications (1)

Application Number Title Priority Date Filing Date
JP50580698A Expired - Lifetime JP4368421B2 (ja) 1996-07-11 1997-06-20 Ｓ―（―）―ｎ―プロパルギル―１―アミノインダンを含む医薬組成物

Country Status (12)

Country Link
US (1) US6277886B1 (cg-RX-API-DMAC10.html)
EP (1) EP0929298B1 (cg-RX-API-DMAC10.html)
JP (1) JP4368421B2 (cg-RX-API-DMAC10.html)
CN (1) CN1149985C (cg-RX-API-DMAC10.html)
AT (1) ATE328590T1 (cg-RX-API-DMAC10.html)
AU (1) AU3188097A (cg-RX-API-DMAC10.html)
CA (1) CA2260037C (cg-RX-API-DMAC10.html)
DE (1) DE69736066T2 (cg-RX-API-DMAC10.html)
HU (1) HU226961B1 (cg-RX-API-DMAC10.html)
IL (1) IL118836A (cg-RX-API-DMAC10.html)
NO (1) NO326052B1 (cg-RX-API-DMAC10.html)
WO (1) WO1998002152A1 (cg-RX-API-DMAC10.html)

Families Citing this family (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5744500A (en) * 1990-01-03 1998-04-28 Teva Pharmaceutical Industries, Ltd. Use of R-enantiomer of N-propargyl-1-aminoindan, salts, and compositions thereof
IL118836A (en) 1996-07-11 2001-01-11 Teva Pharma Pharmaceutical compositions comprising s-(-)-n-propargyl-1-aminoindan
WO2002069977A1 (en) 2001-03-01 2002-09-12 Hollis-Eden Pharmaceuticals, Inc. Use of certain steroids for treatment of blood cell deficiencies
CA2496867A1 (en) 2002-08-28 2004-03-11 Hollis-Eden Pharmaceuticals, Inc. Therapeutic treatment methods
CA2505476C (en) * 2002-11-07 2015-05-26 Technion Research And Development Foundation Ltd. Neuroprotective iron chelators and pharmaceutical compositions comprising them
US7396860B2 (en) 2002-11-15 2008-07-08 Teva Pharmaceutical Industries, Ltd. Use of rasagiline with or without riluzole to treat amyotrophic lateral sclerosis
US8097608B2 (en) * 2003-11-25 2012-01-17 Technion Research And Development Foundation Ltd. Methods for treatment of cardiovascular disorders and diseases
WO2005051371A1 (en) 2003-11-25 2005-06-09 Technion Research & Development Foundation Ltd. Compositions and methods for treatment of cardiovascular disorders and diseases
JP2005232148A (ja) * 2004-02-03 2005-09-02 Technion Research & Development Foundation Ltd 神経保護剤としてプロパルギルアミンの使用
EP1778196A4 (en) * 2004-07-26 2008-12-17 Teva Pharma PHARMACEUTICAL DOSAGES CONTAINING RASAGILINE
US20060025446A1 (en) * 2004-07-27 2006-02-02 Jeffrey Sterling Propargyl nitroxides and indanyl nitroxides and their use for the treatment of neurologic diseases and disorders
CA2582231A1 (en) 2004-09-29 2006-10-19 Hollis-Eden Pharmaceuticals, Inc. Steroid analogs and uses
SI1848415T1 (sl) * 2005-02-17 2013-08-30 Teva Pharmaceutical Industries Ltd. Kombinacijska terapija z glatiramer acetatom in razagilinom za zdravljenje muliple skleroze
KR20170023211A (ko) 2005-02-23 2017-03-02 테바 파마슈티컬 인더스트리즈 리미티드 함량 균일성이 개선된 라사길린 제형
US8263655B2 (en) 2005-10-06 2012-09-11 Technion Research And Development Foundation Ltd Methods for treatment of renal failure
CN101622225B (zh) * 2005-11-17 2015-04-15 泰华制药工业有限公司 炔丙基氨基茚分离方法
US7572834B1 (en) 2005-12-06 2009-08-11 Teva Pharmaceutical Industries, Ltd. Rasagiline formulations and processes for their preparation
CA2634166C (en) 2005-12-09 2016-03-29 Marta Weinstock-Rosin Use of low-dose ladostigil for neuroprotection
JP5701485B2 (ja) 2006-02-21 2015-04-15 テバ ファーマシューティカル インダストリーズ リミティド 多系統萎縮症の治療のためのラサギリンの使用
TW200744576A (en) 2006-02-24 2007-12-16 Teva Pharma Propargylated aminoindans, processes for preparation, and uses thereof
CA2646250A1 (en) 2006-04-03 2007-10-18 Teva Pharmaceutical Industries Ltd. Use of rasagiline for the treatment of restless legs syndrome
EP1892233A1 (de) * 2006-08-18 2008-02-27 Ratiopharm GmbH Neue Salze des Wirkstoffs Rasagilin
EA016820B1 (ru) * 2006-12-14 2012-07-30 Тева Фармасьютикал Индастриз, Лтд. Кристаллическое твердое основание разагилина
KR101077835B1 (ko) * 2006-12-14 2011-10-28 테바 파마슈티컬 인더스트리즈 리미티드 라사길린의 타닌산염
EP1987816A1 (de) * 2007-04-30 2008-11-05 Ratiopharm GmbH Adsorbate eines Rasagilinsalzes mit einem wasserlöslichen Hilfsstoff
EP2194780A4 (en) * 2007-09-05 2010-10-27 Teva Pharma METHOD FOR TREATING GLAUCOMA BY RASAGILINE
US8188149B2 (en) * 2007-09-17 2012-05-29 Teva Pharmaceutical Industries, Ltd. Use of R(+)-N-propargy1-1-aminoindan to treat or prevent hearing loss
SG187455A1 (en) * 2008-01-11 2013-02-28 Teva Pharma Rasagiline formulations, their preparation and use
WO2009122351A2 (en) * 2008-04-01 2009-10-08 Kangwon National University Anti-parkinsonian compounds mppe
JP2011524353A (ja) * 2008-06-10 2011-09-01 テバ ファーマシューティカル インダストリーズ リミティド ラサギリン軟ゼラチンカプセル
BRPI0909894A2 (pt) * 2008-06-13 2015-07-28 Teva Pharma "método de redução da velocidade de progressão de mal de parkinson em um paciente com mal de parkinson em estágio inicial, método de redução da velocidade de progressão de mal de parkinson, método de atraso da necessidade de terapia antiparkinsoniana sintomática em um paciente de mal de parkinson em estágio inicial, método de redução do risco de um paciente com mal de parkinson que necessita de terapia antiparkinsoniana, método de redução do declínio funcional de um paciente com mal de parkinson em estágio inicial, método de redução do declínio funcional em um paciente com mal de parkinson, método de tratamento de um paciente que exibe sinais iniciais de mal de parkinson, método de redução da fadiga em um paciente com mal de parkinson em estágio inicial, método de redução da velocidade de progressão clínica e tratamento de sintomas de mal de parkinson em um paciente com mal de parkinson, rasagilina ou um sal farmaceuticamente aceitável de rasagilina, composição farmacêutica.
AU2009260733B2 (en) * 2008-06-19 2015-01-29 Teva Pharmaceutical Industries, Ltd. Process for purifying rasagiline base
BRPI0909997A2 (pt) 2008-06-19 2015-10-27 Teva Pharma r(+)-n-propargil-1-aminoindano cristalino, composição farmacêutica, processo de secagem de r(+)-n-propargil-1-aminoindano sólido, processo de preparação de uma composição farmacêutica, processo de produção de um lote validado de um produto de farmaco que contém r(+)-n-propargil-1-aminoindano cristalino e pelo menos um veículo farmaceuticamente aceitável para distribuição e processo de prudução de r(+)-n-propargil-1-aminoindano cristalino
US8080584B2 (en) * 2009-01-23 2011-12-20 Teva Pharmaceuticals Industries, Ltd. Delayed release rasagiline citrate formulation
JP2012532843A (ja) 2009-07-09 2012-12-20 ラティオファーム ゲーエムベーハー ラサギリンの塩およびその製剤
RU2607595C2 (ru) 2010-02-03 2017-01-10 Фарма Ту Б Лтд. Составы разагилина с пролонгированным высвобождением и их применение
JP2013537530A (ja) 2010-07-27 2013-10-03 テバ ファーマシューティカル インダストリーズ リミティド ラサギリンシトレートの分散物
WO2012015950A1 (en) 2010-07-27 2012-02-02 Teva Pharmaceutical Industries Ltd. Use of rasagiline for the treatment of olfactory dysfunction
EA201490761A1 (ru) 2011-10-10 2014-11-28 Тева Фармасьютикал Индастриз Лтд. R(+)-n-формилпропаргиламиноиндан
BR112014008552A2 (pt) 2011-10-10 2017-04-18 Teva Pharma r(+)-n-metil-propargilaminoindano
WO2014028868A1 (en) 2012-08-17 2014-02-20 Teva Pharmaceutical Industries Ltd. Parenteral formulation of rasagiline
CN104177610A (zh) * 2013-05-27 2014-12-03 韩文毅 一种非线性的聚合物及其制备和用途
CN104177611A (zh) * 2013-05-27 2014-12-03 韩文毅 一种非线性的聚合物及其制备和用途
CN111333517A (zh) * 2018-12-19 2020-06-26 上海奥博生物医药技术有限公司 一种制备雷沙吉兰的改进方法

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1187017A (en) * 1966-07-16 1970-04-08 Aspro Nicholas Ltd Substituted 1-Amino Indanes and Tetrahydronaphthalens
IL92952A (en) * 1990-01-03 1994-06-24 Teva Pharma R-enantiomers of n-propargyl-1-aminoindan compounds, their preparation and pharmaceutical compositions containing them
US5744500A (en) * 1990-01-03 1998-04-28 Teva Pharmaceutical Industries, Ltd. Use of R-enantiomer of N-propargyl-1-aminoindan, salts, and compositions thereof
IL99759A (en) * 1991-10-16 1997-06-10 Teva Pharma Mono-fluorinated derivatives of n-propargyl-1-aminoindan, their preparation and pharmaceutical compositions containing them
IL111240A (en) * 1993-10-18 2001-10-31 Teva Pharma Salts of r(+) - enantiomers of n- propargyl-1-aminoindan and pharmaceutical compositions comprising them
AU1867095A (en) * 1994-01-10 1995-08-01 Technion Research & Development Foundation Ltd. 1-aminoindan derivatives and compositions thereof
IL115357A (en) * 1995-09-20 2000-01-31 Teva Pharma Stable compositions containing N-propargyl-1-aminoindan and polyhydric alcohols
IL118836A (en) 1996-07-11 2001-01-11 Teva Pharma Pharmaceutical compositions comprising s-(-)-n-propargyl-1-aminoindan

Also Published As

Publication number Publication date
EP0929298A1 (en) 1999-07-21
WO1998002152A1 (en) 1998-01-22
IL118836A (en) 2001-01-11
HUP9904525A3 (en) 2000-12-28
HUP9904525A2 (hu) 2000-11-28
CA2260037A1 (en) 1998-01-22
NO990088D0 (no) 1999-01-08
CN1227486A (zh) 1999-09-01
CN1149985C (zh) 2004-05-19
NO990088L (no) 1999-03-10
CA2260037C (en) 2007-01-23
JP2000514453A (ja) 2000-10-31
AU3188097A (en) 1998-02-09
HU226961B1 (en) 2010-03-29
EP0929298B1 (en) 2006-06-07
DE69736066T2 (de) 2006-12-28
US6277886B1 (en) 2001-08-21
ATE328590T1 (de) 2006-06-15
NO326052B1 (no) 2008-09-08
DE69736066D1 (de) 2006-07-20
IL118836A0 (en) 1996-10-31

Similar Documents

Publication Publication Date Title
JP4368421B2 (ja) Ｓ―（―）―ｎ―プロパルギル―１―アミノインダンを含む医薬組成物
RU2197959C2 (ru) Применение аналогов сибутрамина для снижения уровней липидов
TWI278446B (en) Methods and compositions for modulating alpha adrenergic receptor activity
US6630514B2 (en) Use of R-enantiomer of N-propargyl-1-aminoindan, salts, and compositions thereof
TWI335217B (en) Pharmaceutical formulations of modafinil
EP2156833B1 (en) Prophylactic or therapeutic agent for posterior ocular disease comprising non-ergot selective d2 receptor agonist as active ingredient
CA3081553C (en) Compositions and methods for the treatment of eye disorders
JPH10513455A (ja) 緑内障治療用のデプレニル化合物
HU229507B1 (en) 1,2,3,4-tetrahydro-amino-naphtalenyl- and aminoindan derivatives and pharmaceutical compositions comprising them
JP2008512433A (ja) 炎症性障害及び疼痛の治療
TWI250872B (en) Carbamate compounds for use in preventing or treating bipolar disorder
JP2009196973A (ja) キナゾリノン誘導体又はキノキサリン誘導体を有効成分として含有する後眼部疾患の予防又は治療剤
CA2674144A1 (en) Isosorbide mononitrate derivatives for the treatment of ocular hypertension
JPH09511755A (ja) 新規な治療方法
US6365631B1 (en) Method of treating sleep apnoea
US20040248984A1 (en) Use of $g(b)-adrenoceptor agonists for the treatment of neurodegenerative diseases
US7074961B2 (en) Antidepressants and their analogues as long-acting local anesthetics and analgesics
WO1993000081A1 (en) Optically pure s(-) nadolol for treatment of cardiovascular disorders
RU2192261C2 (ru) Средство консервативного лечения прогрессирующей и осложненной близорукости
JPH07133225A (ja) 毛様体筋緊張緩和剤
CN114096314A (zh) 痴呆症的治疗和预防药
MX2011002727A (es) Composicion farmaceutica novedosa para tratamiento de dolor nociceptivo.
JPH10120569A (ja) 眼疾患予防または治療剤
WO2007114315A1 (ja) 角結膜障害治療剤
JPH10218766A (ja) 涙液分泌促進および角結膜障害治療剤

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20040601

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20040601

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20080129

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20080428

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20080616

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20080529

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20080707

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20080630

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20080811

A524 Written submission of copy of amendment under article 19 pct

Free format text: JAPANESE INTERMEDIATE CODE: A524

Effective date: 20080729

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20080930

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20081225

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20090209

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20090331

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20090728

A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20090826

R150 Certificate of patent or registration of utility model

Free format text: JAPANESE INTERMEDIATE CODE: R150

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20120904

Year of fee payment: 3

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20130904

Year of fee payment: 4

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

EXPY Cancellation because of completion of term